角化细胞癌患者的随访:临床实践指南的系统综述
该系统综述检索了2010年1月至2022年3月的文献,纳入14部关于局限性皮肤角化细胞癌(基底细胞癌和侵袭性鳞状细胞癌)随访频率的指南。各指南对随访频率的推荐共识有限,随访总时长从单次治疗后访视到终身监测不等,多数按复发风险分层推荐。AGREE II评分最高的领域为「范围与目的」,最低为「适用性」。
要点
- 14部指南对角化细胞癌初始治疗后随访频率的推荐共识有限,随访总时长从单次访视到终身监测不等。
- 多数指南按复发风险分层:低危基底细胞癌及未分层指南推荐每6至12个月随访。
- 高危鳞状细胞癌的随访推荐跨度大,涵盖每3个月(5部)、每4个月(1部)、每6个月(6部)或每年(4部)。
核心结论
- 该系统综述发现角化细胞癌初始治疗后随访推荐存在差异,需要随机临床试验来确定最佳随访方案。
研究设计与样本
- 系统综述检索PubMed、MEDLINE和Embase中2010年1月至2022年3月发表的文章,纳入包含局限性皮肤角化细胞癌诊断后随访频率推荐的国家或国际指南,共纳入14部指南。
- 使用AGREE II工具6个领域评估指南质量,并采用PRISMA-P指导报告。
主要发现
- 14部指南对初始角化细胞癌治疗后适当随访频率的共识有限,总体随访时长从单次治疗后访视到终身监测不等。
- 低危基底细胞癌及未按风险分层的指南,随访推荐范围为每6至12个月。
- 高危基底细胞癌:1部指南建议每3个月随访,4部推荐每6个月。
- 低危鳞状细胞癌:5部指南推荐每年随访,3部推荐每6个月,1部推荐每3个月。
- 高危鳞状细胞癌:推荐随访频率包括每3个月(5部指南)、每4个月(1部)、每6个月(6部)或每年(4部);1部指南未使用风险分层并推荐每年筛查。
关键数值与推荐
- AGREE II评分最高的领域为「范围与目的」,评估指南的总体目标;评分最低的领域为「适用性」,评估实施的障碍和促进因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients treated for cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), collectively called keratinocyte carcinoma (KC), are at risk for recurrence, metastasis, and additional primary cutaneous malignant neoplasms. It is unclear how often patients should be seen for follow-up skin examination after initial treatment of KC. OBJECTIVE: To summarize the recommendations and evaluate the methodological quality of clinical practice guidelines for dermatologic follow-up of patients with BCC and invasive SCC. EVIDENCE REVIEW: PubMed, MEDLINE, and Embase were searched for relevant articles published from January 2010 to March 2022. Search terms included guideline, squamous cell carcinoma, and basal cell carcinoma. National or international guidelines containing recommendations for follow-up frequency after a diagnosis of localized cutaneous KC were included. Quality was assessed using the 6 domains of the Appraisal of Guidelines Research and Evaluation II (AGREE II) tool: (1) scope and purpose; (2) stakeholder development; (3) rigor of development; (4) clarity of presentation; (5) applicability; and (6) editorial independence. The Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) was used to guide study reporting. FINDINGS: Among the 14 guidelines meeting eligibility criteria, there was little consensus on the appropriate follow-up frequency after initial KC treatment. Overall duration of follow-up ranged from a single posttreatment visit to lifelong surveillance. Most guidelines stratified their recommendations by recurrence risk. For low-risk BCC and guidelines that did not stratify by risk, follow-up recommendations ranged from every 6 to 12 months. For high-risk BCC, 1 guideline suggested follow-up every 3 months, while 4 recommended every 6 months. For low-risk SCC, 5 guidelines recommended annual follow-up; 3 guidelines, every 6 months; and 1 guideline, every 3 months. For high-risk SCC, recommendations included a range of follow-up frequencies, spanning every 3 months (n = 5 guidelines), 4 months (n = 1), 6 months (n = 6), or annually (n = 4). One guideline did not use risk stratification and recommended annual screening. The highest scoring AGREE II domain was "scope and purpose," which assessed the guideline's overall objectives, and the lowest scoring was "applicability," which assessed barriers and facilitators to implementation. CONCLUSIONS AND RELEVANCE: The findings of this systemic review highlight variations in follow-up recommendations for patients after initial treatment for KC. Randomized clinical trials are needed to define an optimal follow-up regimen.
引用
- Mirali S, Tang E, Drucker AM, et al. Follow-up of Patients With Keratinocyte Carcinoma: A Systematic Review of Clinical Practice Guidelines. JAMA Dermatol. 2023. PMID: 36322063. doi:10.1001/jamadermatol.2022.4590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。